Research Grade Vanalimab (DHD68907)

Catalog No.

DHD68907

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-lambda

Clonality

Monoclonal

Target

Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P25942

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Mitazalimab, ADC-1013, JNJ-64457107, CAS: 2055640-86-1

Clone ID

Vanalimab

Immunomodulatory antibody therapy of cancer: the closer, the better, PMID: 25351746

First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies, PMID: 30664811

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity, PMID: 25316820

The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo, PMID: 33948686

Document Download

Research Grade Vanalimab.pdf